id the concomitant use of venetoclax and idelalisib; venetoclax is a CYP3A4 substrate and idelalisib is a strong CYP3A4 inhibitor. The concomitant use of these agents together is contraindicated during the initial and dose titration phase of venetoclax. If concomitant use of these drugs is required when the patient is on a steady venetoclax dose (after the titration phase), reduce the venetoclax dosage by at least 75% (maximum dose of 100 mg/day). If idelalisib is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study, the venetoclax Cmax and AUC values were increased by 2.3-fold and 6.4-fold, respectively, when a strong CYP3A4 inhibitor was co-administered in NHL patients.
Iloperidone: Avoid the concomitant use of venetoclax and iloperidone; venetoclax is a substrate of P-glycoprotein (P-gp) and iloperidone is an inhibitor of P-gp. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If iloperidone is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Imatinib, STI-571: Avoid the concomitant use of venetoclax and imatinib, STI-571; levels of both drugs may increase. Venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and a P-gp inhibitor and imatinib is a CYP3A4 (moderate) and P-gp substrate with a narrow therapeutic range. Consider alternative agents. If concomitant use of these drugs is required, administer imatinib at least 6 hours before venetoclax and reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If imatinib is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax and imatinib toxicity. In a drug interaction study, the venetoclax Cmax and AUC values were increased by 2.3-fold and 6.4-fold, respectively, when a strong CYP3A4 inhibitor was co-administered in NHL patients. Use of venetoclax with a moderate CYP3A4 inhibitor has not been eva luated.
Indinavir: Avoid the concomitant use of venetoclax and indinavir; venetoclax is a CYP3A4 substrate and indinavir is a strong CYP3A4 inhibitor. The concomitant use of these agents together is contraindicated during the initial and dose titration phase of venetoclax. If concomitant use of these drugs is required when the patient is on a steady venetoclax dose (after the titration phase), reduce the venetoclax dosage by at least 75% (maximum dose of 100 mg/day). If indinavir is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study, the venetoclax Cmax and AUC values were increased by 2.3-fold and 6.4-fold, respectively, when a strong CYP3A4 inhibitor was co-administered in NHL patients.
Isavuconazonium: Avoid th |
